How Dry Eye Disease Develops
Dry eye disease is not simply a matter of not producing enough tears. In many cases, it is driven by a cycle of inflammation on the surface of the eye. When the tear film becomes unstable or insufficient, the exposed surface tissues can become irritated. This irritation triggers the immune system to send inflammatory cells called T-cells to the area. While T-cells normally help fight infection, in chronic dry eye they can cause ongoing damage to the delicate tissues of the eye's surface and the glands that produce tears.
Over time, this inflammation can reduce both the quantity and quality of your tears, which leads to more surface damage, which triggers more inflammation. Breaking this cycle is the primary goal of prescription dry eye treatments like Xiidra and Restasis.
Artificial tears and lubricating eye drops available without a prescription can provide temporary comfort by supplementing your natural tear film. However, they do not address the underlying inflammation that keeps the cycle of dry eye going. For patients with moderate to severe chronic dry eye, a prescription anti-inflammatory eye drop may be necessary to achieve lasting improvement.
Your eye care provider can help determine whether your symptoms are best managed with lubricating drops alone or whether a prescription medication like Xiidra or Restasis would be more appropriate for your situation.
International dry eye treatment guidelines, including those from the Tear Film and Ocular Surface Society (TFOS), organize treatments into a stepwise approach. Step 1 typically includes lifestyle changes, environmental modifications, and over the counter lubricants. When these measures are not sufficient, Step 2 introduces prescription anti-inflammatory therapies. Both Xiidra and Restasis fall into this Step 2 category, meaning they are recommended when basic measures alone have not provided adequate relief.
This stepwise framework helps eye care providers tailor treatment to the severity of each patient's condition, starting with the least invasive options and moving to more targeted therapies as needed.
How Xiidra Works
Xiidra (lifitegrast) belongs to a class of medications called integrin antagonists. To understand how it works, it helps to know a bit about how inflammation damages the eye's surface. When inflammatory T-cells travel to the eye, they need to physically attach to the surface tissue in order to cause damage. They do this by using proteins on their surface called integrins, which act like tiny anchors.
Xiidra works by blocking these integrin proteins, preventing T-cells from latching onto the eye's surface. By stopping this attachment, Xiidra interrupts the inflammatory process at the point where tissue damage would otherwise occur. Think of it as removing the anchor points so the inflammatory cells cannot hold on and cause harm.
Xiidra is typically applied as one drop in each eye, twice a day, approximately 12 hours apart. It comes in single use vials, which means each vial is used once and then discarded. This design eliminates the need for preservatives in the solution, which can be helpful for patients whose eyes are sensitive to preservative ingredients.
Consistency is important with Xiidra, as with any prescription eye drop. Using it regularly as directed gives the medication the best chance of controlling inflammation and improving your symptoms over time.
One of the notable characteristics of Xiidra is its relatively fast onset of action. Clinical research suggests that some patients begin to notice improvement in their dry eye symptoms within two to six weeks of starting treatment. This quicker response can be encouraging for patients who are eager to experience relief.
However, it is important to understand that individual responses can vary. Some patients may notice changes sooner, while others may need more time. Your eye care provider will want to monitor your progress and make adjustments to your treatment plan as needed.
How Restasis Works
Restasis (cyclosporine) is a calcineurin inhibitor, which means it works through a different pathway than Xiidra. Rather than blocking T-cells from attaching to the eye's surface, Restasis works further upstream in the inflammatory process. It prevents inflammatory T-cells from multiplying within the tear-producing glands.
By reducing the number of inflammatory cells in and around the tear glands, Restasis helps these glands recover and function more normally. Over time, this can lead to an increase in your natural tear production. In other words, Restasis helps your body make more of its own tears by calming the inflammation that was suppressing tear production.
Restasis is also applied as one drop in each eye, twice daily, roughly 12 hours apart. Like Xiidra, it is available in preservative-free single use vials. Some formulations may also be available in multi-dose bottles depending on the specific product your provider prescribes.
Because Restasis works by gradually reducing inflammation in the tear glands, it requires consistent daily use to be effective. Skipping doses or stopping the medication early can interrupt the process and delay your results.
Restasis typically requires a longer period of consistent use before patients notice significant improvement. Clinical studies indicate that it generally takes three to six months of regular use for Restasis to reach its full effectiveness. During this time, the medication is steadily reducing inflammation and allowing the tear glands to recover, but the changes may be gradual.
Because of this longer timeline, patience and commitment to the treatment plan are especially important with Restasis. Many eye care providers will recommend using lubricating artificial tears alongside Restasis during this initial period to help manage symptoms while the medication builds to its full effect.
The reason Restasis takes longer to show results relates to how it works. Because it targets the multiplication of inflammatory cells rather than blocking their immediate activity, the existing inflammatory cells need time to naturally clear out before the full benefit becomes apparent. This is a gradual process, but the long-term results are well supported by clinical research.
Comparing Effectiveness
When researchers compare the long-term effectiveness of Xiidra and Restasis, the evidence suggests that both medications are highly effective at managing chronic dry eye disease. The TFOS DEWS III guidelines, which represent an international consensus on dry eye management, position both medications as proven Step 2 therapies for breaking the cycle of ocular surface inflammation.
While the two medications take different paths to get there, the destination is similar. Both can meaningfully reduce inflammation, improve the health of the eye's surface, and relieve symptoms like dryness, burning, grittiness, and irritation.
The most notable difference in effectiveness is timing rather than magnitude. Xiidra's ability to provide faster initial symptom relief, sometimes within two to six weeks, can be a significant advantage for patients who need quicker results. Restasis, while requiring three to six months to reach peak effectiveness, offers comparable long-term outcomes once it has had time to fully work.
This difference in onset can influence which medication a provider recommends depending on a patient's situation. For example, a patient with severe symptoms who needs rapid relief may benefit from starting with Xiidra, while a patient who can be more patient with their treatment timeline may do equally well with either option.
It is worth noting that not every patient responds the same way to either medication. Some patients may find that one works better for their particular type of dry eye than the other. The choice between Xiidra and Restasis is rarely about one being universally better. Instead, it is about finding which specific medication works best with your individual eye chemistry and inflammatory profile.
If one medication does not provide adequate relief after a fair trial period, your eye care provider may recommend switching to the other. This trial and evaluation approach is a normal and expected part of managing chronic dry eye.
Side Effects and Safety
Both Xiidra and Restasis have been extensively studied in clinical trials and have demonstrated strong long-term safety profiles. The side effects associated with both medications are primarily limited to the area around the eyes and tend to be mild and temporary. Serious systemic side effects with either medication are uncommon.
This favorable safety profile is one reason that both medications are widely prescribed and recommended in international treatment guidelines. Your eye care provider can discuss the specific risks and benefits as they apply to your health history.
The most frequently reported side effect of Restasis is a temporary burning or stinging sensation when the drop is applied. This sensation typically lasts only a few minutes and tends to decrease over time as the eyes adjust to the medication. Some patients also experience mild redness or a watery discharge after applying the drops.
These side effects are generally manageable and often improve as the eyes become accustomed to the medication. If burning or stinging is bothersome, your eye care provider may suggest strategies to reduce discomfort, such as refrigerating the vials before use.
Xiidra shares the potential for mild irritation at the application site, including brief stinging or discomfort after instillation. However, Xiidra has a unique side effect that sets it apart from Restasis. Some patients experience dysgeusia, which is a temporary unusual or altered taste in the mouth shortly after applying the drops. This taste change is harmless and typically resolves quickly, but it can be unexpected if you are not prepared for it.
Some patients also report occasional brief blurred vision immediately after applying Xiidra. This effect is temporary and usually clears within a few minutes. It is generally recommended to avoid driving or other activities requiring clear vision until your sight returns to normal after each application.
For both medications, side effects tend to be most noticeable during the first few weeks of treatment and often improve as your eyes adjust. If side effects are significant enough to affect your quality of life or your willingness to continue treatment, talk to your eye care provider. They can offer strategies to reduce discomfort or may recommend trying the other medication to see if it is better tolerated.
Some helpful tips for managing application-related discomfort include:
- Keeping your eye drop vials in the refrigerator, as cool drops can feel more soothing
- Closing your eyes gently for one to two minutes after applying drops to help the medication absorb
- Pressing lightly on the inner corner of your eye after application to reduce the amount of medication that drains into the throat, which may help with taste changes from Xiidra
- Timing your doses so that any brief blurred vision does not interfere with important activities
Practical Considerations for Choosing
Both Xiidra and Restasis are prescription medications, and access can vary depending on your health plan. The TFOS consensus notes that formulary coverage is often a major practical factor in the decision between these two medications. Some plans may cover one but not the other, or may require prior authorization for one of them.
Before starting either medication, it is a good idea to check with your pharmacy to understand your options. Your eye care provider's office may also be able to help you navigate available support programs.
Beyond clinical effectiveness, your personal preferences and lifestyle may also play a role in choosing between Xiidra and Restasis. Consider factors such as how quickly you need symptom relief, how you feel about the possibility of a temporary taste change with Xiidra, and whether you prefer a medication that helps increase your natural tear production over time as Restasis does.
Some patients prefer Xiidra's faster onset because they want to feel improvement sooner. Others prefer Restasis because its mechanism of boosting natural tear production appeals to them. Neither preference is wrong. The best medication is the one that you will use consistently and that works well for your eyes.
The decision between Xiidra and Restasis is best made in partnership with your eye care provider. They can evaluate the specific characteristics of your dry eye, consider your medical history, review your coverage options, and help you weigh the pros and cons of each option. At Washington Eye Institute, our multidisciplinary ophthalmology and optometry team works together to develop personalized treatment plans that address each patient's unique needs.
In addition to prescription eye drops, our practice offers a range of dry eye treatments including IPL (intense pulsed light) therapy, punctal plugs, and comprehensive eye exams to monitor your condition over time. Your provider may recommend combining a prescription drop with one or more of these therapies for the best possible results.
For some patients, prescription eye drops alone may not fully resolve their symptoms. Dry eye disease can have multiple contributing factors, and a combination approach is often the most effective strategy. If you are using Xiidra or Restasis and still experiencing significant discomfort, your eye care provider may suggest adding complementary treatments.
IPL therapy, for example, can help improve the function of the oil-producing glands in the eyelids, which play a critical role in maintaining a healthy tear film. Punctal plugs are tiny devices placed in the tear drainage channels to help your natural tears stay on the surface of the eye longer. These treatments can work alongside prescription drops to provide more comprehensive relief.
Frequently Asked Questions
Using both medications simultaneously is not a standard approach and is generally not recommended without specific guidance from your eye care provider. Because both medications target inflammation through different pathways, there could theoretically be a rationale for combining them in certain situations. However, this would need to be carefully evaluated and monitored by your provider. In most cases, patients use one medication at a time and switch to the other if the first does not provide adequate results.
Both Xiidra and Restasis are typically used as ongoing, long-term treatments. Chronic dry eye disease is usually a condition that requires continuous management rather than a short course of treatment. If you stop using either medication, the underlying inflammation can return, and your symptoms may come back. Your eye care provider will help you determine the appropriate duration of treatment based on how your eyes respond.
Yes, many eye care providers recommend using preservative-free artificial tears alongside prescription eye drops. This is especially helpful during the early weeks of treatment when the prescription medication has not yet reached its full effect. If you use both, it is generally best to wait at least 15 minutes between applying different types of eye drops so that one does not wash the other away.
Mild side effects like brief stinging or the temporary taste change associated with Xiidra are common and often improve over time. However, if side effects are severe, persistent, or significantly affecting your daily life, contact your eye care provider. They can help you determine whether the side effects are likely to improve, suggest strategies to manage them, or recommend switching to the other medication.
The availability of generic or alternative formulations for these medications can change over time. Some cyclosporine-based formulations are available, though they may not be identical to the original product. Your eye care provider and pharmacist can help you understand what options are currently available and whether any of them would be appropriate for your situation. Checking with your pharmacy can also clarify which formulations may be available to you.
Your provider will consider several factors when recommending Xiidra or Restasis. These include the severity and type of your dry eye, how quickly you need relief, your medical history, and any other medications you are taking. They may also consider whether you have had any previous experience with either medication. The goal is to find the option that gives you the best combination of effectiveness and tolerability for your specific situation.